Abstract | PURPOSE: The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. METHODS: PZA was administered at a dose of 750 mg/m2 intravenously over three hours every three weeks. RESULTS: Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic. CONCLUSION: PZA at the dose and schedule employed has insignificant activity in this population.
|
Authors | S C Plaxe, J A Blessing, J A Lucci, J A Hurteau |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 19
Issue 1
Pg. 77-80
( 2001)
ISSN: 0167-6997 [Print] United States |
PMID | 11291835
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Acridines
- Antineoplastic Agents
- Pyrazoles
- NSC 366140
|
Topics |
- Acridines
(administration & dosage, adverse effects, therapeutic use)
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, pathology)
- Female
- Humans
- Middle Aged
- Pyrazoles
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
- Uterine Cervical Neoplasms
(drug therapy, pathology)
|